YES1 and cancer: This observation may have important implication in cancer therapy involving SFK catalytic inhibitors and may explain, at least in part, the discrepancy observed between the dramatic loss of tumorigenicity in c-Yes-depleted cells compared to mild effects of SFK kinase inhibitors in vivo.